We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Researchers Discover New Data on Protein Kinase A

By LabMedica International staff writers
Posted on 22 Oct 2014
By employing X-rays and neutron beams, a team of researchers have gleaned new information about protein kinase A (PKA), an omnipresent master control protein that helps regulate basic cellular functions such as energy consumption and interactions with neurotransmitters, hormones, and drugs. More...


The scientists who conducted the study were from the University of California (UC), San Diego School of Medicine (USA), University of Utah (Salt Lake City, USA), and Oak Ridge US National Laboratory (Oak Ridge, TN, USA). “Mutations in PKA can lead to a variety of different human diseases, including cancers, metabolic and cardiovascular diseases and diseases involving the brain and nervous system,” said senior author Susan Taylor, PhD, professor of chemistry, biochemistry and pharmacology at UC San Diego and international authority on PKA. “Developing treatments and cures for these diseases depends upon knowing how the switch works.”

The findings were published October 10, 2014, issue of the Journal of Biological Chemistry. The researchers concentrated on one of four types of PKA called II-beta, which is found mostly in the brain and in fat, where it may play a significant role in obesity and diet-induced insulin-resistance associated with type 2 diabetes. All forms of PKA are regulated by a signaling molecule called cyclic adenosine monophosphate (cAMP). Many cellular functions are based upon altering amounts of cAMP within cells. PKA is the molecular sensor for cAMP, modulating cell activity according to cAMP levels.

The scientists investigated which parts of the II-beta protein were needed to determine its overall shape, internal construction and ability to change shape—factors that control function. II-beta is very compact when inactive but extends and separates into subunits when it senses cAMP. “A key question regarding the architecture of the II-beta was whether both of its cAMP-sensing mechanisms were needed for the unique changes in shape that it undergoes with cAMP,” said first author Donald K. Blumenthal, PhD, associate professor of pharmacology and toxicology at the University of Utah College of Pharmacy.

Researchers removed one of II-beta’s cAMP sensors and then documented its ability to change shape in response to cAMP, using small-angle X-ray and advanced neutron scattering imaging technologies at Oak Ridge’s high flux isotope reactor in Tennessee. They discovered that the protein could still change shape with just one sensor and that its internal architecture stayed similar to II-beta protein with both its cAMP sensors.

The findings further narrow and define the major components of II-beta and identify new areas for further investigation. Prof. Taylor reported that the collaborative, multi-team effort also demonstrated the importance of using different techniques in an iterative way to unravel the dynamic characteristics of complex systems.

Related Links:

University of California, San Diego School of Medicine 
University of Utah
Oak Ridge US National Laboratory



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.